Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12188/12940
DC FieldValueLanguage
dc.contributor.authorHalimi Vesaen_US
dc.contributor.authorDaci Armonden_US
dc.contributor.authorRidova Nevenkaen_US
dc.contributor.authorPanovska-Stavridis Irinaen_US
dc.contributor.authorStevanovic Milenaen_US
dc.contributor.authorFilipce Venkoen_US
dc.contributor.authorDimovski Aleksandaren_US
dc.contributor.authorGrozdanova Aleksandraen_US
dc.date.accessioned2021-05-31T12:20:37Z-
dc.date.available2021-05-31T12:20:37Z-
dc.date.issued2020-09-21-
dc.identifier.urihttp://hdl.handle.net/20.500.12188/12940-
dc.language.isoenen_US
dc.publisherJournal of Pharmaceutical Policy and Practiceen_US
dc.subjectCOVID-19, Remdesivir, Clinical practice, Clinical trials, Expanded access, Compassionate use, Early access scheme, Emergency use, Conditional approvalen_US
dc.titleThe use of remdesivir outside of clinical trials during the COVID-19 pandemicen_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1186/s40545-020-00258-8-
item.fulltextWith Fulltext-
item.grantfulltextopen-
Appears in Collections:Faculty of Pharmacy: Journal Articles
Files in This Item:
File Description SizeFormat 
s40545-020-00258-8.pdf360.96 kBAdobe PDFView/Open
Show simple item record

Page view(s)

34
checked on May 3, 2024

Download(s)

11
checked on May 3, 2024

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.